IIM
NTLA icon

INTECH Investment Management’s Intellia Therapeutics NTLA Stock Holding History

INTECH Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$481K Sell
28,404
-5,300
-16% -$74.2K ﹤0.01% 1364
2026
Q1 		$432K Sell
33,704
-24,325
-42% -$310K ﹤0.01% 1402
2025
Q4 		$522K Buy
58,029
+13,442
+30% +$185K ﹤0.01% 1497
2025
Q3 		$770K Sell
44,587
-12,757
-22% -$157K 0.01% 1335
2025
Q2 		$538K Sell
57,344
-6,819
-11% -$56K 0.01% 1571
2025
Q1 		$456K Buy
64,163
+29,619
+86% +$299K ﹤0.01% 1663
2024
Q4 		$403K Buy
34,544
+6,341
+22% +$99K ﹤0.01% 1684
2024
Q3 		$580K Buy
+28,203
New +$650K 0.01% 1148

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

INTECH Investment Management's NTLA Position: Q2 2026 in Review

INTECH Investment Management reduced its Intellia Therapeutics (NTLA) stake by 16% in Q2 2026, selling an estimated $74.2K and leaving 28,404 shares worth $481K. The position accounts for ﹤0.01% of the portfolio, ranked #1364.

INTECH Investment Management first reported a position in NTLA in Q3 2024 and has held it in 8 quarters since. The position peaked at $770K in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • INTECH Investment Management held 28,404 shares of Intellia Therapeutics worth $481K as of Q2 2026.
  • INTECH Investment Management sold 5,300 Intellia Therapeutics shares in Q2 2026, an estimated $74.2K.
  • Intellia Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1364 holding.
  • INTECH Investment Management first reported a position in Intellia Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • INTECH Investment Management's Intellia Therapeutics position peaked at $770K in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.